Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders

31Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Molecular biological insights have led to a fundamental understanding of the underlying genomic mechanisms of nervous system disease. These findings have resulted in the identification of therapeutic genes that can be packaged in viral capsids for the treatment of a variety of neurological conditions, including neurodegenerative, metabolic, and enzyme deficiency disorders. Recent data have demonstrated that gene-carrying viral vectors (most often adeno-associated viruses) can be effectively distributed by convection-enhanced delivery (CED) in a safe, reliable, targeted, and homogeneous manner across the blood-brain barrier. Critically, these vectors can be monitored using real-time MRI of a co-infused surrogate tracer to accurately predict vector distribution and transgene expression at the perfused site. The unique properties of CED of adeno-associated virus vectors allow for cell-specific transgene manipulation of the infused anatomical site and/or widespread interconnected sites via antero- and/or retrograde transport. The authors review the convective properties of viral vectors, associated technology, and clinical applications.

Cite

CITATION STYLE

APA

Lonser, R. R., Akhter, A. S., Zabek, M., Elder, J. B., & Bankiewicz, K. S. (2021, June 1). Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders. Journal of Neurosurgery. American Association of Neurological Surgeons. https://doi.org/10.3171/2020.4.JNS20701

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free